Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Citation
Mahaffey KW, Jardin MJ, Bompoint S, et al. Circulation 2019;140:739–50.